Editas Medicine, Inc. EDIT

US Biotechnology

$2.56 ▼ -6.91% ($-0.19)

🔥 High Short Interest 🎢 High Beta

Open $2.72

Prev Close $2.75

Day Range $2.48 – $2.75

52W Range $1.66 – $3.94

Market Cap $422.35M

Beta 2.17

EPS (TTM) $-0.74

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2016-02-03
Shares Out.	153,580,000
Website	editasmedicine.com ↗
Phone	13026587581
Employees	87
Revenue	$11.9M
Gross Profit	$11.9M
Net Income	-$18.2M
Free Cash Flow	-$120.6M
Total Assets	$237.4M
Total Liabilities	$132.1M
Equity	$105.3M

About Editas Medicine, Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Editas Medicine, Inc. is a publicly traded company under the ticker symbol EDIT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.